EXELIXIS INC (EXEL)
US30161Q1040 - Common Stock
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
4 Magnificent Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
Phenomenal deals can still be found, even with the Nasdaq Composite climbing to a new all-time high.
2 Biotech Stocks to Buy Hand Over Fist in March
These stocks are worth buying in most months of the year.
3 Cutting-Edge Biotech Stocks Sitting on the Brink of Success
With excellent financial health and great prospects, these three biotech stocks just may be the the next stars of the sector.
4 Thrilling Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
The growth-driven Nasdaq Composite has entered a new bull market, but plain-as-day deals can still be found.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
Friday 2/23 Insider Buying Report: EXEL, HPP
2 Stocks Under $30 to Buy and Hold
You don't need to be a millionaire to get started. Investing on a budget can work, too.
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
The 3 Best Biotech Stocks to Buy in February 2024
The best biotech stocks to buy offer consistent growth opportunities and resist the influence of singular drug successes.
4 Appealing Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-driven Nasdaq Composite hasn't put the 2022 bear market entirely in the rearview mirror, which means opportunistic investors can still find bargains.
Exelixis Larger Than S&P 500 Component Whirlpool
Exelixis Becomes Oversold (EXEL)
EXEL Crosses Below Key Moving Average Level
Exelixis (EXEL) Q4 2023 Earnings Call Transcript
EXEL earnings call for the period ending December 31, 2023.
Exelixis Non-GAAP EPS of $0.33 beats by $0.02, revenue of $480M beats by $2.08M (NASDAQ:EXEL)
Exelixis beats expectations with Q4 financial results: Non-GAAP EPS of $0.33, revenue of $480M (+13.2% Y/Y), and 2024 guidance of $1.825B-$1.925B.
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
Notable earnings after Tuesday's close
Major earnings expected after the bell on Tuesday include:Ford Motor Company (F)Gilead Sciences (GILD)Amgen (AMGN)Enphase Energy (ENPH) Snap (SNAP)Other...
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
Noteworthy Monday Option Activity: SG, AUPH, EXEL
3 Top-Rated Biotech Stocks Wall Street Analysts Are Loving Now: January 2024
These top-rated biotech stocks are going to be in high demand in January and in every other month in 2024.